Who is sponsoring NCT03360006?

NCT03360006 is sponsored by AbbVie.

What condition does NCT03360006 study?

NCT03360006 studies Acute Myeloid Leukemia (AML).

What is the status of NCT03360006?

NCT03360006 is currently TERMINATED.

Last reviewed 2021-03-24 · How we verify

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

NCT03360006 PHASE1 TERMINATED

This is an open-label, Phase 1, dose-escalation (Segment 1) and expansion (Segment 2) study to determine the maximum tolerated dose (MTD) and/or the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-744 in participants with relapsed/refractory Acute Myeloid Leukemia (AML).

Details

Lead sponsor	AbbVie
Phase	PHASE1
Status	TERMINATED
Enrolment	30
Start date	Fri Mar 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Dec 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Acute Myeloid Leukemia (AML)

Interventions

ABBV-744

Countries

United States